PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 17, 2025Applied Sciences2 citationsOpen Access

Development and Characterization of Chitosan–Polyvinylpyrrolidone Nanoparticles for Antimicrobial Drug Delivery Applications

View Full Paper
PEPablo Sebastián EspinelLSLilian SpencerFAFernando Alberício

Key Points

  • Significant inhibition against E. coli and Staphylococcus aureus was shown by JH1, JH2, honey, and propolis-loaded nanoparticles.
  • The optimal chitosan-polyvinylpyrrolidone ratio for stable nanoparticles was determined to be 1:0.5 with 44–60% encapsulation efficiency.
  • Characterization methods included FTIR, TGA, XRD, and AFM, confirming the successful development of the nanoparticles.
  • Sustained drug release over 180 minutes in artificial gastric fluid indicates a potential for effective therapeutic use.

Abstract

Chitosan (CS) and polyvinylpyrrolidone (PVP)-based nanoparticles (NPs) are promising carriers for drug delivery due to their biocompatibility, biodegradability, and intrinsic antimicrobial properties. This study explores CS-PVP NPs for the encapsulation and controlled release of synthetic compounds (bis-THTT, JH1, JH2) and natural antimicrobials (honey and propolis). NPs were synthesized via ionic gelation, optimizing CS:PVP and CS-PVP:sodium tripolyphosphate (TPP) ratios. The optimal formulation (CS:PVP 1:0.5) produced stable, homogeneous NPs. Characterization was performed using FTIR, TGA, XRD, and AFM. Encapsulation efficiencies ranged from 44–60%. Antimicrobial activity was evaluated against Escherichia coli and Staphylococcus aureus, showing significant inhibition for JH1-, JH2-, honey-, and propolis-loaded NPs against E. coli. Cytotoxicity assays on 3T3 fibroblasts confirmed the biocompatibility of all formulations at 5 and 10 µg/mL. In vitro release studies in artificial gastric fluid (pH 1.78) demonstrated sustained drug release over 180 min. These results confirm that CS-PVP NPs can effectively encapsulate and protect both synthetic and natural bioactive compounds, enhancing their therapeutic potential. The developed nanosystems represent a versatile and safe platform for antimicrobial drug delivery and may support future applications in biomedical therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Espinel et al. (2025) studied this question.

synapsesocial.com/papers/68d45b1b31b076d99fa5d74bhttps://doi.org/10.3390/app151810103
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Piperazine linked chitosan schiff base nanoparticles as a novel antibiofilm and antibacterial strategy against clinically relevant pathogens2026
  2. 2Phytochemical-Based Nanoantioxidants Stabilized with Polyvinylpyrrolidone for Enhanced Antibacterial, Antioxidant, and Anti-Inflammatory Activities2024 · 1 citations
  3. 3Chitosan and PVP: Versatile Biopolymers for Drug Delivery and Advanced Materials2024
  4. 4RSM optimization of Tetracycline-loaded PLGA nanoparticles in chitosan/HPMC hydrogels for sustained antibacterial delivery2026
  5. 5Novel Ti surface coated with <scp>PVA</scp> hydrogel and chitosan nanoparticles with antibacterial drug release: An experimental in vitro study2024